This article is more than 5 years old. Information may no longer be current.
Thrombectomy catheter approved to treat DVT in peripheral veins
Click Here to Manage Email Alerts
Boston Scientific announced that a thrombectomy catheter has received FDA approval and a CE Mark for treatment of deep vein thrombosis in large-diameter upper- and lower-limb peripheral veins.
The catheter (ZelanteDVT, Boston Scientific) was designed to remove large venous clots and facilitate quick restoration of blood flow, which could lead to shorter procedural time, fast symptom relief and reduction in late complications, according to a company press release.
The catheter set is intended for use with a console (AngioJet Ultra, Boston Scientific) to break apart and remove thrombus from lower-extremity and iliofemoral veins or upper-extremity peripheral veins ≥ 6 mm in diameter, and for use with a technique (AngioJet PowerPulse, Boston Scientific) for infusion of fluids into the peripheral vascular system, according to the release.
“There has been a clinical need for a stronger thrombectomy catheter to support treatment modalities in addressing challenging cases of deep vein thrombosis,” Mitchell Silver, DO, FACC, from Riverside Hospital, Columbus, Ohio, said in the release. “The unique features of the ZelanteDVT catheter make it well-suited to treat a wide range of thrombotic occlusions, thus potentially decreasing bleeding risks and reducing patients’ need for intensive care stays.”
Disclosure: Silver reports no relevant financial disclosures.